CoChat

Potential Therapeutic Targets for Combination Antibody Therapy Against Staphylococcus aureus Infections

Ke, Sharon, Kil, Hyein, Roggy, Conner, Shields, Ty, Quinn, Zachary, Quinn, Alyssa P., Small, James M., Towne, Francina D., Brooks, Amanda E., Brooks, Benjamin D. · 2024 · Antibiotics
Cited by 17

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Despite the significant advances in antibiotic treatments and therapeutics, Staphylococcus aureus (S. aureus) remains a formidable pathogen, primarily due to its rapid acquisition of antibiotic resistance. Known for its array of virulence factors, including surface proteins that promote adhesion to host tissues, enzymes that break down host barriers, and toxins that contribute to immune evasion and tissue destruction, S. aureus poses a serious health threat. Both the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) classify S. aureus as an ESKAPE pathogen, recognizing it as a critical threat to global health. The increasing prevalence of drug-resistant S. aureus underscores the need for new therapeutic strategies. This review discusses a promising approach that combines monoclonal antibodies targeting multiple S. aureus epitopes, offering synergistic efficacy in treating infections. Such strategies aim to reduce the capacity of the pathogen to develop resistance, presenting a potent adjunct or alternative to conventional antibiotic treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/antibiotics13111046

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 116

  1. Lam, 2023, The Golden Grapes of Wrath–Staphylococcus aureus Bacteremia: A Clinical Review, Am. J. Med., 136, 19, 10.1016/j.amjmed.2022.09.017 · DOI
  2. Lakhundi, 2018, Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology, Clin. Microbiol. Rev., 31, e00020-18, 10.1128/CMR.00020-18 · DOI · Paper page
  3. Tong, 2015, Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management, Clin. Microbiol. Rev., 28, 603, 10.1128/CMR.00134-14 · DOI · Paper page
  4. Chand, U., Priyambada, P., and Kushawaha, P.K. (2023). Staphylococcus aureus Vaccine Strategy: Promise and Challenges. Microbiol. Res., 271. · DOI
  5. Douglas, E.J.A., and Laabei, M. (2023). Staph Wars: The Antibiotic Pipeline Strikes Back. Microbiology, 169. · DOI · Paper page
  6. Linz, M.S., Mattappallil, A., Finkel, D., and Parker, D. (2023). Clinical Impact of Staphylococcus aureus Skin and Soft Tissue Infections. Antibiotics, 12. · DOI · Paper page
  7. Liu, K., Wang, C., Zhou, X., Guo, X., Yang, Y., Liu, W., Zhao, R., and Song, H. (2024). Bacteriophage Therapy for Drug-Resistant Staphylococcus aureus Infections. Front. Cell. Infect. Microbiol., 14. · DOI · Paper page
  8. Jiang, 2023, Virulence Attributes of Successful Methicillin-Resistant Staphylococcus aureus Lineages, Clin. Microbiol. Rev., 36, e00148-22, 10.1128/cmr.00148-22 · DOI · Paper page
  9. Turner, 2019, Methicillin-Resistant Staphylococcus aureus: An Overview of Basic and Clinical Research, Nat. Rev. Microbiol., 17, 203, 10.1038/s41579-018-0147-4 · DOI · Paper page
  10. Thampi, 2015, Multicenter Study of Health Care Cost of Patients Admitted to Hospital with Staphylococcus aureus Bacteremia: Impact of Length of Stay and Intensity of Care, Am. J. Infect. Control, 43, 739, 10.1016/j.ajic.2015.01.031 · DOI
  11. Miller, 2024, ESKAPE Pathogens: Antimicrobial Resistance, Epidemiology, Clinical Impact and Therapeutics, Nat. Rev. Microbiol., 22, 598, 10.1038/s41579-024-01054-w · DOI · Paper page
  12. Karauzum, 2017, Adaptive Immunity against Staphylococcus aureus, Curr. Top. Microbiol. Immunol., 409, 419
  13. Brown, A.F., Murphy, A.G., Lalor, S.J., Leech, J.M., O’Keeffe, K.M., Aogáin, M.M., O’Halloran, D.P., Lacey, K.A., Tavakol, M., and Hearnden, C.H. (2015). Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection. PLOS Pathog., 11. · DOI · Paper page
  14. Francis, 2021, Identification of CD4+ T Cell Epitopes from Staphylococcus aureus Secretome Using Immunoinformatic Prediction and Molecular Docking, BioTechnologia, 102, 43, 10.5114/bta.2021.103761 · DOI
  15. Guo, Y., Song, G., Sun, M., Wang, J., and Wang, Y. (2020). Prevalence and Therapies of Antibiotic-Resistance in Staphylococcus aureus. Front. Cell. Infect. Microbiol., 10. · DOI · Paper page
  16. Shariati, A., Dadashi, M., Moghadam, M.T., van Belkum, A., Yaslianifard, S., and Darban-Sarokhalil, D. (2020). Global Prevalence and Distribution of Vancomycin Resistant, Vancomycin Intermediate and Heterogeneously Vancomycin Intermediate Staphylococcus aureus Clinical Isolates: A Systematic Review and Meta-Analysis. Sci. Rep., 10. · DOI · Paper page
  17. Cavalcanti, 2010, Teicoplanin versus Vancomycin for Proven or Suspected Infection, Cochrane Database Syst. Rev., 6, CD007022
  18. Esposito, S., Blasi, F., Curtis, N., Kaplan, S., Lazzarotto, T., Meschiari, M., Mussini, C., Peghin, M., Rodrigo, C., and Vena, A. (2023). New Antibiotics for Staphylococcus aureus Infection: An Update from the World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Italian Society of Anti-Infective Therapy (SITA). Antibiotics, 12. · DOI
  19. Chan, 2015, Ceftobiprole- and Ceftaroline-Resistant Methicillin-Resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 59, 2960, 10.1128/AAC.05004-14 · doi:10.1128/aac.05004-14
  20. Minter, 2023, Executive Summary: State-of-The-Art Review: Contemporary Management of Staphylococcus aureus Bacteremia: Controversies in Clinical Practice, Clin. Infect. Dis., 77, 1489, 10.1093/cid/ciad525 · doi:10.1093/cid/ciad525
  21. Liu, 2011, Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children, Clin. Infect. Dis., 52, e18, 10.1093/cid/ciq146 · DOI · Paper page
  22. Lambert, 2011, IDSA Guidelines on the Treatment of MRSA Infections in Adults and Children, AFP, 84, 455
  23. Dinges, M.M., Orwin, P.M., and Schlievert, P.M. (2000). Exotoxins of Staphylococcus aureus. Clin. Microbiol. Rev., 13. · DOI · Paper page
  24. Proctor, L.L., Ward, W.L., Roggy, C.S., Koontz, A.G., Clark, K.M., Quinn, A.P., Schroeder, M., Brooks, A.E., Small, J.M., and Towne, F.D. (2021). Potential Therapeutic Targets for Combination Antibody Therapy against Pseudomonas aeruginosa Infections. Antibiotics, 10. · DOI
  25. Otto, 2014, Staphylococcus aureus Toxins, Curr. Opin. Microbiol., 17, 32, 10.1016/j.mib.2013.11.004 · DOI · Paper page
  26. Howden, 2023, Staphylococcus aureus Host Interactions and Adaptation, Nat. Rev. Microbiol., 21, 380, 10.1038/s41579-023-00852-y · DOI · Paper page
  27. Plotkin, S.A., Orenstein, W.A., and Offit, P.A. (2018). Plotkin’s Vaccines, Elsevier.
  28. Krakauer, T. (2019). Staphylococcal Superantigens: Pyrogenic Toxins Induce Toxic Shock. Toxins, 11. · DOI
  29. Murray, 2005, Recognition and Management of Staphylococcus aureus Toxin-Mediated Disease, Intern. Med. J., 35, S106, 10.1111/j.1444-0903.2005.00984.x · doi:10.1111/j.1444-0903.2005.00984.x
  30. Brooks, B.D., Brooks, A.E., and Grainger, D.W. (2012). Antimicrobial Medical Devices in Preclinical Development and Clinical Use. Biomaterials Associated Infection, Springer. · DOI
  31. Joh, 1999, Role of Fibronectin-Binding MSCRAMMs in Bacterial Adherence and Entry into Mammalian Cells, Matrix Biol., 18, 211, 10.1016/S0945-053X(99)00025-6 · DOI · Paper page
  32. Nilsson, 1998, Vaccination with a Recombinant Fragment of Collagen Adhesin Provides Protection against Staphylococcus aureus-Mediated Septic Death, J. Clin. Investig., 101, 2640, 10.1172/JCI1823 · DOI · Paper page
  33. Schennings, 1993, Immunization with Fibronectin Binding Protein from Staphylococcus aureus Protects against Experimental Endocarditis in Rats, Microb. Pathog., 15, 227, 10.1006/mpat.1993.1073 · DOI
  34. Perkins, 1998, Clumping Factor B (ClfB), a New Surface-Located Fibrinogen-Binding Adhesin of Staphylococcus aureus, Mol. Microbiol., 30, 245, 10.1046/j.1365-2958.1998.01050.x · DOI · Paper page
  35. Nanavaty, 1998, The Fibrinogen-Binding MSCRAMM (Clumping Factor) of Staphylococcus aureus Has a Ca2+-Dependent Inhibitory Site, J. Biol. Chem., 273, 6821, 10.1074/jbc.273.12.6821 · DOI · Paper page
  36. McDevitt, 1995, Identification of the Ligand-Binding Domain of the Surface-Located Fibrinogen Receptor (Clumping Factor) of Staphylococcus aureus, Mol. Microbiol., 16, 895, 10.1111/j.1365-2958.1995.tb02316.x · DOI · Paper page
  37. Hartford, 2001, Identification of Residues in the Staphylococcus aureus Fibrinogen-Binding MSCRAMM Clumping Factor A (ClfA) That Are Important for Ligand Binding *, J. Biol. Chem., 276, 2466, 10.1074/jbc.M007979200 · DOI · Paper page
  38. Deivanayagam, 2002, A Novel Variant of the Immunoglobulin Fold in Surface Adhesins of Staphylococcus aureus: Crystal Structure of the Fibrinogen-Binding MSCRAMM, Clumping Factor A, EMBO J., 21, 6660, 10.1093/emboj/cdf619 · DOI · Paper page
  39. Vastag, 2001, New Vaccine Decreases Rate of Nosocomial Infections, JAMA, 285, 1565, 10.1001/jama.285.12.1565-JMN0328-3-1 · doi:10.1001/jama.285.12.1565-jmn0328-3-1
  40. Shkreta, 2006, DNA Immunization of Dairy Cows with the Clumping Factor A of Staphylococcus aureus, Vaccine, 24, 1997, 10.1016/j.vaccine.2005.11.033 · doi:10.1016/j.vaccine.2005.11.033
  41. Ganesh, 2011, Structural and Biochemical Characterization of Staphylococcus aureus Clumping Factor B/Ligand Interactions, J. Biol. Chem., 286, 25963, 10.1074/jbc.M110.217414 · DOI · Paper page
  42. Schaffer, 2006, Immunization with Staphylococcus aureus Clumping Factor B, a Major Determinant in Nasal Carriage, Reduces Nasal Colonization in a Murine Model, Infect. Immun., 74, 2145, 10.1128/IAI.74.4.2145-2153.2006 · DOI · Paper page
  43. Barbu, E.M., Ganesh, V.K., Gurusiddappa, S., Mackenzie, R.C., Foster, T.J., Sudhof, T.C., and Höök, M. (2010). β-Neurexin Is a Ligand for the Staphylococcus aureus MSCRAMM SdrC. PLoS Pathog., 6. · DOI · Paper page
  44. Kerrigan, 2002, Multiple Mechanisms for the Activation of Human Platelet Aggregation by Staphylococcus aureus: Roles for the Clumping Factors ClfA and ClfB, the Serine–Aspartate Repeat Protein SdrE and Protein A, Mol. Microbiol., 44, 1033, 10.1046/j.1365-2958.2002.02935.x · DOI · Paper page
  45. Huesca, 2002, Adhesion and Virulence Properties of Epidemic Canadian Methicillin-Resistant Staphylococcus aureus Strain 1: Identification of Novel Adhesion Functions Associated with Plasmin-Sensitive Surface Protein, J. Infect. Dis., 185, 1285, 10.1086/340123 · DOI
  46. Roche, 2003, The Staphylococcus aureus Surface Protein SasG and Its Homologues Promote Bacterial Adherence to Human Desquamated Nasal Epithelial Cells, Microbiology, 149, 2759, 10.1099/mic.0.26412-0 · DOI · Paper page
  47. Josefsson, 2005, The Surface Protein Pls of Methicillin-Resistant Staphylococcus aureus Is a Virulence Factor in Septic Arthritis, Infect. Immun., 73, 2812, 10.1128/IAI.73.5.2812-2817.2005 · doi:10.1128/iai.73.5.2812-2817.2005
  48. Hussain, 2009, Expression of Pls (Plasmin Sensitive) in Staphylococcus aureus Negative for Pls Reduces Adherence and Cellular Invasion and Acts by Steric Hindrance, J. Infect. Dis., 200, 107, 10.1086/599359 · DOI · Paper page
  49. Tung, 2000, A Bone Sialoprotein-Binding Protein from Staphylococcus aureus: A Member of the Staphylococcal Sdr Family, Biochem. J., 345, 611, 10.1042/bj3450611 · doi:10.1042/bj3450611 · Paper page
  50. Hynes, 2000, Hyaluronidases of Gram-Positive Bacteria, FEMS Microbiol. Lett., 183, 201, 10.1111/j.1574-6968.2000.tb08958.x · doi:10.1111/j.1574-6968.2000.tb08958.x · Paper page
  51. Kumar, N.G., Contaifer, D., Wijesinghe, D.S., and Jefferson, K.K. (2021). Staphylococcus aureus Lipase 3 (SAL3) Is a Surface-Associated Lipase That Hydrolyzes Short Chain Fatty Acids. PLoS ONE, 16. · DOI
  52. Alkuraythi, D. (2024). Virulence Factors and Pathogenicity of Staphylococcus aureus, IntechOpen. · DOI
  53. Taj, Z., and Chattopadhyay, I. (2024, October 03). Staphylococcus aureus Virulence Factors and Biofilm Components: Synthesis, Structure, Function and Inhibitors. Available online: https://colab.ws/articles/10.1007%2F978-981-99-8799-3_8. · DOI
  54. Sibbald, 2006, Mapping the Pathways to Staphylococcal Pathogenesis by Comparative Secretomics, Microbiol. Mol. Biol. Rev., 70, 755, 10.1128/MMBR.00008-06 · DOI · Paper page
  55. Quiblier, C., Seidl, K., Roschitzki, B., Zinkernagel, A.S., Berger-Bächi, B., and Senn, M.M. (2013). Secretome Analysis Defines the Major Role of SecDF in Staphylococcus aureus Virulence. PLoS ONE, 8. · DOI
  56. Kanonenberg, K., Spitz, O., Erenburg, I.N., Beer, T., and Schmitt, L. (2018). Type I Secretion System—It Takes Three and a Substrate. FEMS Microbiol. Lett., 365. · DOI
  57. Famelis, 2021, Type VII Secretion Systems: Structure, Functions and Transport Models, Nat. Rev. Microbiol., 19, 567, 10.1038/s41579-021-00560-5 · DOI
  58. Yamada, 2007, Analysis of Twin-Arginine Translocation Pathway Homologue in Staphylococcus aureus, Curr. Microbiol., 55, 14, 10.1007/s00284-006-0461-3 · doi:10.1007/s00284-006-0461-3
  59. Tran, 2023, Current Therapies and Challenges for the Treatment of Staphylococcus aureus Biofilm-Related Infections, Pharmacotherapy, 43, 816, 10.1002/phar.2806 · DOI
  60. Le, K.Y., and Otto, M. (2015). Quorum-Sensing Regulation in Staphylococci—An Overview. Front. Microbiol., 6. · DOI · Paper page
  61. Aboelnaga, 2024, Deciphering the Dynamics of Methicillin-Resistant Staphylococcus aureus Biofilm Formation: From Molecular Signaling to Nanotherapeutic Advances, Cell Commun. Signal, 22, 188, 10.1186/s12964-024-01511-2 · DOI
  62. Tuon, F.F., Suss, P.H., Telles, J.P., Dantas, L.R., Borges, N.H., and Ribeiro, V.S.T. (2023). Antimicrobial Treatment of Staphylococcus aureus Biofilms. Antibiotics, 12. · DOI · Paper page
  63. Otto, 2014, Phenol-Soluble Modulins, Int. J. Med. Microbiol., 304, 164, 10.1016/j.ijmm.2013.11.019 · DOI · Paper page
  64. Queck, S.Y., Khan, B.A., Wang, R., Bach, T.-H.L., Kretschmer, D., Chen, L., Kreiswirth, B.N., Peschel, A., DeLeo, F.R., and Otto, M. (2009). Mobile Genetic Element-Encoded Cytolysin Connects Virulence to Methicillin Resistance in MRSA. PLOS Pathog., 5. · DOI · Paper page
  65. Cheung, 2014, Phenol-Soluble Modulins–Critical Determinants of Staphylococcal Virulence, FEMS Microbiol. Rev., 38, 698, 10.1111/1574-6976.12057 · DOI · Paper page
  66. Romeo, T. (2008). Staphylococcal Biofilms. Bacterial Biofilms, Springer. · doi:10.1007/978-3-540-75418-3
  67. Zhu, Z., Hu, Z., Li, S., Fang, R., Ono, H.K., and Hu, D.-L. (2023). Molecular Characteristics and Pathogenicity of Staphylococcus aureus Exotoxins. Int. J. Mol. Sci., 25. · DOI
  68. Hanzelmann, 2016, Toll-like Receptor 2 Activation Depends on Lipopeptide Shedding by Bacterial Surfactants, Nat. Commun., 7, 12304, 10.1038/ncomms12304 · DOI · Paper page
  69. Ivancic, 2016, Characterization of Structural Elements in Native Autoinducing Peptides and Non-Native Analogues That Permit the Differential Modulation of AgrC-Type Quorum Sensing Receptors in Staphylococcus aureus, Org. Biomol. Chem., 14, 113, 10.1039/C5OB01735A · DOI · Paper page
  70. Wu, K., Conly, J., McClure, J.-A., Kurwa, H.A., and Zhang, K. (2020). Arginine Catabolic Mobile Element in Evolution and Pathogenicity of the Community-Associated Methicillin-Resistant Staphylococcus aureus Strain USA300. Microorganisms, 8. · DOI · Paper page
  71. Maddela, N.R., and García, L.C. (2021). Drug Resistance Mechanism in Staphylococcus aureus. Innovations in Biotechnology for a Sustainable Future, Springer International Publishing.
  72. Kim, C., Mwangi, M., Chung, M., Milheirço, C., Lencastre, H.d., and Tomasz, A. (2013). The Mechanism of Heterogeneous Beta-Lactam Resistance in MRSA: Key Role of the Stringent Stress Response. PLoS ONE, 8. · DOI · Paper page
  73. Ohwada, 1999, DNA Vaccination by mecA Sequence Evokes an Antibacterial Immune Response against Methicillin-Resistant Staphylococcus aureus, J. Antimicrob. Chemother., 44, 767, 10.1093/jac/44.6.767 · doi:10.1093/jac/44.6.767
  74. Stephen, J., Salam, F., Lekshmi, M., Kumar, S.H., and Varela, M.F. (2023). The Major Facilitator Superfamily and Antimicrobial Resistance Efflux Pumps of the ESKAPEE Pathogen Staphylococcus aureus. Antibiotics, 12. · DOI
  75. Pollitt, E.J.G., Crusz, S.A., and Diggle, S.P. (2015). Staphylococcus aureus Forms Spreading Dendrites That Have Characteristics of Active Motility. Sci. Rep., 5. · DOI
  76. Kizaki, H., Omae, Y., Tabuchi, F., Saito, Y., Sekimizu, K., and Kaito, C. (2016). Cell-Surface Phenol Soluble Modulins Regulate Staphylococcus aureus Colony Spreading. PLoS ONE, 11. · DOI
  77. Liu, C.-C., and Lin, M.-H. (2020). Involvement of Heme in Colony Spreading of Staphylococcus aureus. Front. Microbiol., 11. · DOI
  78. Kumari, P., Nath, Y., Murty, U.S., Ravichandiran, V., and Mohan, U. (2020). Sortase A Mediated Bioconjugation of Common Epitopes Decreases Biofilm Formation in Staphylococcus aureus. Front. Microbiol., 11. · DOI
  79. Speziale, P., Pietrocola, G., Foster, T.J., and Geoghegan, J.A. (2014). Protein-Based Biofilm Matrices in Staphylococci. Front. Cell. Infect. Microbiol., 4. · DOI · Paper page
  80. Frees, 2004, Clp ATPases Are Required for Stress Tolerance, Intracellular Replication and Biofilm Formation in Staphylococcus aureus, Mol. Microbiol., 54, 1445, 10.1111/j.1365-2958.2004.04368.x · DOI · Paper page
  81. Sinha, 1999, Fibronectin-Binding Protein Acts as Staphylococcus aureus Invasin via Fibronectin Bridging to Integrin Alpha5beta1, Cell. Microbiol., 1, 101, 10.1046/j.1462-5822.1999.00011.x · DOI · Paper page
  82. Dziewanowska, 1999, Fibronectin Binding Protein and Host Cell Tyrosine Kinase Are Required for Internalization of Staphylococcus aureus by Epithelial Cells, Infect. Immun., 67, 4673, 10.1128/IAI.67.9.4673-4678.1999 · DOI · Paper page
  83. Fowler, 2000, Cellular Invasion by Staphylococcus aureus Involves a Fibronectin Bridge between the Bacterial Fibronectin-Binding MSCRAMMs and Host Cell Beta1 Integrins, Eur. J. Cell Biol., 79, 672, 10.1078/0171-9335-00104 · DOI · Paper page
  84. Dziewanowska, 2000, Staphylococcal Fibronectin Binding Protein Interacts with Heat Shock Protein 60 and Integrins: Role in Internalization by Epithelial Cells, Infect. Immun., 68, 6321, 10.1128/IAI.68.11.6321-6328.2000 · doi:10.1128/iai.68.11.6321-6328.2000 · Paper page
  85. Tsompanidou, E., Denham, E.L., Sibbald, M.J.J.B., Yang, X., Seinen, J., Friedrich, A.W., Buist, G., and van Dijl, J.M. (2012). The Sortase A Substrates FnbpA, FnbpB, ClfA and ClfB Antagonize Colony Spreading of Staphylococcus aureus. PLoS ONE, 7. · DOI
  86. Thappeta, K.R.V., Zhao, L.N., Nge, C.E., Crasta, S., Leong, C.Y., Ng, V., Kanagasundaram, Y., Fan, H., and Ng, S.B. (2020). In-Silico Identified New Natural Sortase A Inhibitors Disrupt S. Aureus Biofilm Formation. Int. J. Mol. Sci., 21. · DOI
  87. Liu, 2009, Molecular Pathogenesis of Staphylococcus aureus Infection, Pediatr. Res., 65, 71R, 10.1203/PDR.0b013e31819dc44d · DOI · Paper page
  88. Hejazian, 2024, An Update on Glycerophosphodiester Phosphodiesterases; From Bacteria to Human, Protein J., 43, 187, 10.1007/s10930-024-10190-4 · DOI
  89. Jung, 2008, Necrotizing Pneumonia Caused by Panton-Valentine Leucocidin-Producing Staphylococcus aureus Originating from a Bartholin’s Abscess, Infect. Dis. Obstet. Gynecol., 2008, 491401, 10.1155/2008/491401 · DOI
  90. Chen, Y., Liu, Z., Lin, Z., Lu, M., Fu, Y., Liu, G., and Yu, B. (2023). The Effect of Staphylococcus aureus on Innate and Adaptive Immunity and Potential Immunotherapy for S. Aureus-Induced Osteomyelitis. Front. Immunol., 14. · DOI
  91. Goodyear, 2005, B Cell Superantigens: A Microbe’s Answer to Innate-like B Cells and Natural Antibodies, Springer Semin. Immun., 26, 463, 10.1007/s00281-004-0190-2 · DOI
  92. Kim, 2010, Nontoxigenic Protein A Vaccine for Methicillin-Resistant Staphylococcus aureus Infections in Mice, J. Exp. Med., 207, 1863, 10.1084/jem.20092514 · DOI · Paper page
  93. Olson, 2013, Staphylococcus aureus Nuclease Is an SaeRS-Dependent Virulence Factor, Infect. Immun., 81, 1316, 10.1128/IAI.01242-12 · DOI · Paper page
  94. Guerra, F.E., Borgogna, T.R., Patel, D.M., Sward, E.W., and Voyich, J.M. (2017). Epic Immune Battles of History: Neutrophils vs. Staphylococcus aureus. Front. Cell. Infect. Microbiol., 7. · DOI · Paper page
  95. Gustafsson, E., Haas, P.-J., Walse, B., Hijnen, M., Furebring, C., Ohlin, M., van Strijp, J.A., and van Kessel, K.P. (2009). Identification of Conformational Epitopes for Human IgG on Chemotaxis Inhibitory Protein of Staphylococcus aureus. BMC Immunol., 10. · doi:10.1186/1471-2172-10-13
  96. Gustafsson, 2010, Directed Evolution of Chemotaxis Inhibitory Protein of Staphylococcus aureus Generates Biologically Functional Variants with Reduced Interaction with Human Antibodies, Protein Eng. Des. Sel., 23, 91, 10.1093/protein/gzp062 · DOI
  97. Eisenbeis, J., Saffarzadeh, M., Peisker, H., Jung, P., Thewes, N., Preissner, K.T., Herrmann, M., Molle, V., Geisbrecht, B.V., and Jacobs, K. (2018). The Staphylococcus aureus Extracellular Adherence Protein Eap Is a DNA Binding Protein Capable of Blocking Neutrophil Extracellular Trap Formation. Front. Cell. Infect. Microbiol., 8. · DOI
  98. Chavakis, 2002, Staphylococcus aureus Extracellular Adherence Protein Serves as Anti-Inflammatory Factor by Inhibiting the Recruitment of Host Leukocytes, Nat. Med., 8, 687, 10.1038/nm728 · DOI · Paper page
  99. Shukla, 2017, Staphylococcus aureus Biofilm Removal by Targeting Biofilm-Associated Extracellular Proteins, Indian J. Med. Res., 146, S1, 10.4103/ijmr.IJMR_410_15 · DOI
  100. Nemeth, 1995, Antibodies to Capsular Polysaccharides Are Not Protective against Experimental Staphylococcus aureus Endocarditis, Infect. Immun., 63, 375, 10.1128/iai.63.2.375-380.1995 · doi:10.1128/iai.63.2.375-380.1995
  101. Fattom, 1996, A Staphylococcus aureus Capsular Polysaccharide (CP) Vaccine and CP-Specific Antibodies Protect Mice against Bacterial Challenge, Infect. Immun., 64, 1659, 10.1128/iai.64.5.1659-1665.1996 · DOI · Paper page
  102. Fattom, 2015, Efficacy Profile of a Bivalent Staphylococcus aureus Glycoconjugated Vaccine in Adults on Hemodialysis: Phase III Randomized Study, Hum. Vaccin. Immunother., 11, 632, 10.4161/hv.34414 · DOI
  103. Li, 2015, USA300 and USA500 Clonal Lineages of Staphylococcus aureus Do Not Produce a Capsular Polysaccharide Due to Conserved Mutations in the Cap5 Locus, mBio, 6, e02585-14, 10.1128/mBio.02585-14 · DOI · Paper page
  104. Hassanzadeh, 2023, Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The Staphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical Trial, Clin. Infect. Dis., 77, 312, 10.1093/cid/ciad218 · DOI
  105. Clegg, J., Soldaini, E., McLoughlin, R.M., Rittenhouse, S., Bagnoli, F., and Phogat, S. (2021). Staphylococcus aureus Vaccine Research and Development: The Past, Present and Future, Including Novel Therapeutic Strategies. Front. Immunol., 12. · DOI · Paper page
  106. McKenney, 1999, Broadly Protective Vaccine for Staphylococcus aureus Based on an in Vivo-Expressed Antigen, Science, 284, 1523, 10.1126/science.284.5419.1523 · DOI · Paper page
  107. Cavacini, 2006, Characterization of the Opsonic and Protective Activity against Staphylococcus aureus of Fully Human Monoclonal Antibodies Specific for the Bacterial Surface Polysaccharide Poly-N-Acetylglucosamine, Infect. Immun., 74, 2742, 10.1128/IAI.74.5.2742-2750.2006 · DOI
  108. Douglas, 2023, Novel Antimicrobial Strategies to Treat Multi-drug Resistant Staphylococcus aureus Infections, Microb. Biotechnol., 16, 1456, 10.1111/1751-7915.14268 · DOI · Paper page
  109. Weisman, 2009, Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections, in Very-Low-Birth-Weight Neonates, Antimicrob. Agents Chemother., 53, 2879, 10.1128/AAC.01565-08 · DOI · Paper page
  110. Suzuki, 2012, Wall Teichoic Acid Protects Staphylococcus aureus from Inhibition by Congo Red and Other Dyes, J. Antimicrob. Chemother., 67, 2143, 10.1093/jac/dks184 · DOI · Paper page
  111. Kırmusaoğlu, S. (2016). Staphylococcal Biofilms: Pathogenicity, Mechanism and Regulation of Biofilm Formation by Quorum-Sensing System and Antibiotic Resistance Mechanisms of Biofilm-Embedded Microorganisms. Microbial Biofilms—Importance and Applications, IntechOpen. · DOI
  112. Weidenmaier, 2017, Structure and Function of Surface Polysaccharides of Staphylococcus aureus, Curr. Top. Microbiol. Immunol., 409, 57
  113. Parthasarathy, A.K., Chougale, R.A., Parthasarathy, A.K., and Chougale, R.A. (2021). Antibiotic Resistant Staphylococcus aureus. Insights into Drug Resistance in Staphylococcus aureus, IntechOpen. · DOI
  114. Vestergaard, M., Frees, D., and Ingmer, H. (2019). Antibiotic Resistance and the MRSA Problem. Microbiol. Spectr., 7. · DOI · Paper page
  115. Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., and Wu, H.-C. (2020). Development of Therapeutic Antibodies for the Treatment of Diseases. J. Biomed. Sci., 27. · DOI · Paper page
  116. Jones, 2016, Targeted Localized Use of Therapeutic Antibodies: A Review of Non-Systemic, Topical and Oral Applications, Crit. Rev. Biotechnol., 36, 506

Cited by

See all 17

Metadata

Authors
Ke, S., Kil, H., Roggy, C., Shields, T., Quinn, Z., Quinn, A. P., Small, J. M., Towne, F. D., Brooks, A. E., & Brooks, B. D.
Venue
Antibiotics
Publisher
MDPI AG
Published
2024-11-05
Volume
13
Issue
11
Pages
1046
ISSN
2079-6382
Cited by
17
References
6
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potential Therapeutic Targets for Combination Antibody Therapy Against Staphylococcus aureus Infections. https://app.cochat.ai/papers/10.3390/antibiotics13111046
The paper
Ke, S., Kil, H., Roggy, C., Shields, T., Quinn, Z., Quinn, A. P., Small, J. M., Towne, F. D., Brooks, A. E., & Brooks, B. D. (2024). Potential Therapeutic Targets for Combination Antibody Therapy Against Staphylococcus aureus Infections. Antibiotics. https://doi.org/10.3390/antibiotics13111046

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.